+

ES2166368T3 - Inmunoconjugados. - Google Patents

Inmunoconjugados.

Info

Publication number
ES2166368T3
ES2166368T3 ES94119712T ES94119712T ES2166368T3 ES 2166368 T3 ES2166368 T3 ES 2166368T3 ES 94119712 T ES94119712 T ES 94119712T ES 94119712 T ES94119712 T ES 94119712T ES 2166368 T3 ES2166368 T3 ES 2166368T3
Authority
ES
Spain
Prior art keywords
preferredly
biologically active
active binding
new
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94119712T
Other languages
English (en)
Inventor
Ilka Von Hoegen
Uwe Hofmann
Carlota-Silvia Jaeggle
Wolfgang Strittmatter
Joerg Stadlmueller
Siegfried Matzku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2166368T3 publication Critical patent/ES2166368T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5406IL-4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5418IL-7
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PRESENTE INVENCION RELATA LAS NUEVAS PROTEINAS DE FUSION QUE CONSTAN DE UN ELEMENTO OBJETIVO ASOCIADO A TUMOR PREFERENTEMENTE UN ANTICUERPO MONOCLONAL O UN FRAGMENTO DE ELLO QUE RECONOCE LA MOLECULA QUE ESTA PREFERENTEMENTE EXPRESADA EN LAS CELULAS DE TUMOR HUMANAS TALES COMO EL RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDERMAL HUMANO (EGFR), Y UN LIGANDO ACTIVO BIOLOGICAMENTE TAL COMO UN FACTOR DE DIFERENCIACION Y/O CRECIMIENTO. LA PROTEINA DE FUSION RESULTANTE DEBE SER USADA PARA DISTRIBUIR EL LIGANDO ACTIVO BIOLOGICAMENTE A UNA CELULA O TEJIDO OBJETO ESPECIFICO. LOS NUEVOS INMUNOCONJUGADOS PUEDEN SER APLICADOS EN LA TERAPIA DE TUMOR.
ES94119712T 1993-12-24 1994-12-14 Inmunoconjugados. Expired - Lifetime ES2166368T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93120865 1993-12-24

Publications (1)

Publication Number Publication Date
ES2166368T3 true ES2166368T3 (es) 2002-04-16

Family

ID=8213530

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94119712T Expired - Lifetime ES2166368T3 (es) 1993-12-24 1994-12-14 Inmunoconjugados.

Country Status (19)

Country Link
US (1) US6979726B1 (es)
EP (1) EP0659439B1 (es)
JP (2) JPH07223968A (es)
KR (1) KR950016781A (es)
AT (1) ATE207366T1 (es)
AU (1) AU688817B2 (es)
CA (1) CA2138928C (es)
CZ (1) CZ289099B6 (es)
DE (1) DE69428764T2 (es)
DK (1) DK0659439T3 (es)
ES (1) ES2166368T3 (es)
HU (1) HU219680B (es)
NO (1) NO315903B1 (es)
PL (1) PL178793B1 (es)
PT (1) PT659439E (es)
RU (1) RU2129018C1 (es)
SK (1) SK283494B6 (es)
UA (1) UA41888C2 (es)
ZA (1) ZA9410282B (es)

Families Citing this family (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
RU2219942C2 (ru) * 1996-02-24 2003-12-27 Берингер Ингельхайм Интернациональ Гмбх Лекарственный состав с иммуномодуляторным действием, содержащий пептиды и вспомогательные средства
AU4208897A (en) * 1996-09-16 1998-04-02 Merck Patent Gmbh Oligocistronic expression system for the production of heteromeric proteins
PT1189641E (pt) 1999-06-25 2009-11-04 Genentech Inc Anticorpos anti-erbb2 humanizados e tratamento com anticorpos anti-erbb2
DK1246846T3 (da) * 1999-12-23 2008-12-08 Zymogenetics Inc Oplöselig interleukin-20-receptor
KR100812658B1 (ko) * 2000-02-25 2008-03-13 더 거번먼트 오브 더 유나이티드 스테이츠, 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비스즈 향상된 세포독성 및 수율의 항-이지에프알브이 3,에스씨에프브이에스, 이에 기초한 면역독소, 및 이의 이용방법
RU2196604C1 (ru) * 2001-12-21 2003-01-20 Северин Евгений Сергеевич Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
ES2392525T3 (es) 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
JP5020636B2 (ja) 2003-11-06 2012-09-05 シアトル ジェネティックス, インコーポレイテッド リガンドに結合体化可能なモノメチルバリン化合物
RU2265027C2 (ru) * 2003-11-14 2005-11-27 Государственный научный центр вирусологии и биотехнологии "Вектор" (ГНЦ ВБ "Вектор") Опухоль-адресованный пептид
CA2551915C (en) 2003-12-30 2015-06-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Il-7 fusion proteins
WO2005070020A2 (en) 2004-01-23 2005-08-04 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
US20060034840A1 (en) 2004-04-08 2006-02-16 Agus David B ErbB antagonists for pain therapy
EP2527460B1 (en) 2004-05-27 2014-12-24 The Regents of The University of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
EP1791565B1 (en) 2004-09-23 2016-04-20 Genentech, Inc. Cysteine engineered antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR20070094928A (ko) 2005-01-21 2007-09-27 제넨테크, 인크. Her 항체의 고정 용량 투여법
PL1850874T3 (pl) 2005-02-23 2014-03-31 Genentech Inc Wydłużanie czasu do progresji choroby lub przeżycia u chorych na raka jajnika stosujących pertuzumab
AR053272A1 (es) 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
PT1966238E (pt) 2005-12-30 2012-07-31 Merck Patent Gmbh Uso de hsp70 como um regulador de atividade enzimática
EP1966245B1 (en) 2005-12-30 2011-05-18 Merck Patent GmbH Anti-cd19 antibodies with reduced immunogenicity
RU2451521C2 (ru) * 2006-06-16 2012-05-27 Онкотерапи Сайенс, Инк. Sparc-производные антигенные пептиды отторжения опухоли и лекарственные средства, содержащие их
US20100008910A1 (en) 2006-09-12 2010-01-14 John Chant Methods and compositions for the diagnosis and treatment of cancer
TWI352199B (en) 2007-03-02 2011-11-11 Genentech Inc Predicting response to a her inhibitor
DK2171090T3 (da) 2007-06-08 2013-06-10 Genentech Inc Genekspressionsmarkører for tumorresistens over for HER2-inhibitorbehandling
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至her2結構域ii之抗體及其酸性變異體的組合物
MX2011009729A (es) 2009-03-20 2011-10-14 Genentech Inc Anticuerpos anti-her.
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
RU2016105962A (ru) 2009-12-04 2018-11-23 Дженентек, Инк. Мультиспецифические антитела, аналоги антител, композиции и способы
CA2781578A1 (en) 2010-01-12 2011-07-21 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof
WO2011103242A1 (en) 2010-02-18 2011-08-25 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
US8617557B2 (en) 2010-03-12 2013-12-31 The Regents Of The University Of California Antibody fusion with IL-12 proteins with disrupted heparin-binding activity
RU2012141536A (ru) 2010-03-17 2014-04-27 Ф. Хоффманн-Ля Рош Аг Имидазопиридины, композиции и способы применения
JP2013528787A (ja) 2010-04-16 2013-07-11 ジェネンテック, インコーポレイテッド Pi3k/aktキナーゼ経路インヒビターの効果の予測バイオマーカーとしてのfox03a
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012031027A1 (en) 2010-08-31 2012-03-08 Genentech, Inc. Biomarkers and methods of treatment
BR112013006016A2 (pt) 2010-09-15 2016-06-07 Hoffmann La Roche compostos de azabenzotiazol, composições e métodos de uso
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
US9238690B2 (en) 2010-10-29 2016-01-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
WO2012058588A2 (en) 2010-10-29 2012-05-03 Immunogen, Inc. Novel egfr-binding molecules and immunoconjugates thereof
EP2637692A4 (en) 2010-11-12 2014-09-10 Scott & White Healthcare ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8
KR20140009259A (ko) 2010-11-19 2014-01-22 에프. 호프만-라 로슈 아게 피라졸로피리딘 및 tyk2 억제제로서 이의 용도
WO2012085176A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
KR20140047160A (ko) 2011-08-12 2014-04-21 에프. 호프만-라 로슈 아게 인다졸 화합물, 조성물 및 사용 방법
RU2014109093A (ru) 2011-08-17 2015-09-27 Дженентек, Инк. Антитела против нейрегулина и их применение
WO2013041539A1 (en) 2011-09-20 2013-03-28 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
CA2856411A1 (en) 2011-11-21 2013-05-30 Immunogen, Inc. Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
MX2014006529A (es) 2011-11-30 2014-11-25 Genentech Inc Mutaciones de erbb3 en cancer.
MX2014011500A (es) 2012-03-27 2014-12-05 Genentech Inc Diagnosticos y tratamientos relacionados a inhibidores her3.
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
JP2016510751A (ja) 2013-03-06 2016-04-11 ジェネンテック, インコーポレイテッド 抗がん剤耐性を治療及び予防する方法
WO2014139326A1 (en) 2013-03-13 2014-09-18 Genentech, Inc. Pyrazolo compounds and uses thereof
AU2014239903A1 (en) 2013-03-14 2015-09-17 Genentech, Inc. Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use
WO2014153030A2 (en) 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
RS58666B1 (sr) * 2013-03-15 2019-06-28 Abbvie Deutschland Formulacije konjugata leka anti-egfr antitela
MX2015011899A (es) 2013-03-15 2016-05-05 Genentech Inc Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
CN104250302B (zh) * 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
CN105611933B (zh) 2013-09-05 2019-01-25 基因泰克公司 抗增生性化合物
AR097894A1 (es) 2013-10-03 2016-04-20 Hoffmann La Roche Inhibidores terapéuticos de cdk8 o uso de los mismos
JP6677638B2 (ja) 2013-10-18 2020-04-08 ジェネンテック, インコーポレイテッド 抗rspo2及び/又はrspo3抗体及びそれらの使用
WO2015095418A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
CN106102774A (zh) 2013-12-17 2016-11-09 豪夫迈·罗氏有限公司 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
MA39776A (fr) 2014-03-24 2017-02-01 Hoffmann La Roche Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
PT3126394T (pt) 2014-03-31 2019-12-19 Hoffmann La Roche Anticorpos anti-ox40 e métodos de utilização
SG11201608106PA (en) 2014-03-31 2016-10-28 Genentech Inc Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
JP6673848B2 (ja) * 2014-04-03 2020-03-25 セレクティスCellectis 癌免疫療法のためのcd33特異的キメラ抗原受容体
WO2016036873A1 (en) 2014-09-05 2016-03-10 Genentech, Inc. Therapeutic compounds and uses thereof
WO2016044694A1 (en) 2014-09-19 2016-03-24 Genentech, Inc. Use of cbp/ep300 and bet inhibitors for treatment of cancer
WO2016057924A1 (en) 2014-10-10 2016-04-14 Genentech, Inc. Pyrrolidine amide compounds as histone demethylase inhibitors
SG11201703448QA (en) 2014-11-03 2017-05-30 Genentech Inc Assays for detecting t cell immune subsets and methods of use thereof
BR112017009159A2 (pt) 2014-11-03 2018-03-06 Genentech, Inc. métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40
EP3215536A1 (en) 2014-11-06 2017-09-13 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and tigit inhibitors
MA40940A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
EP3218376B1 (en) 2014-11-10 2019-12-25 Genentech, Inc. Bromodomain inhibitors and uses thereof
MA40943A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
SG11201703605QA (en) 2014-11-17 2017-06-29 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
EP3632915A1 (en) 2014-11-27 2020-04-08 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
WO2016091891A1 (en) 2014-12-09 2016-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against axl
RU2710735C2 (ru) 2014-12-23 2020-01-10 Дженентек, Инк. Композиции и способы лечения и диагностики резистентного к химиотерапии рака
WO2016109546A2 (en) 2014-12-30 2016-07-07 Genentech, Inc. Methods and compositions for prognosis and treatment of cancers
EP3242874B1 (en) 2015-01-09 2018-10-31 Genentech, Inc. Pyridazinone derivatives and their use in the treatment of cancer
EP3242875B1 (en) 2015-01-09 2022-02-23 Genentech, Inc. 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
WO2016112284A1 (en) 2015-01-09 2016-07-14 Genentech, Inc. (piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
WO2016115097A2 (en) 2015-01-12 2016-07-21 Children's Medical Center Corporation Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
EP3250571B1 (en) 2015-01-29 2022-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
CN107438593B (zh) 2015-01-30 2020-10-30 基因泰克公司 治疗化合物及其用途
SG11201706667XA (en) 2015-02-18 2017-09-28 Hoffmann La Roche Immunoconjugates for specific induction of t cell cytotoxicity against a target cell
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
AU2016246695A1 (en) 2015-04-07 2017-10-26 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
HUE051815T2 (hu) 2015-05-12 2021-03-29 Hoffmann La Roche Terápiás és diagnosztikai eljárások rákra
CN107532217A (zh) 2015-05-29 2018-01-02 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
JP2018518483A (ja) 2015-06-08 2018-07-12 ジェネンテック, インコーポレイテッド 抗ox40抗体及びpd−1軸結合アンタゴニストを使用して癌を治療する方法
MX2017014740A (es) 2015-06-08 2018-08-15 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40.
KR102689256B1 (ko) 2015-06-17 2024-07-30 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
PL3341376T3 (pl) 2015-08-26 2021-08-02 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Skondensowane związki tricykliczne jako inhibitory kinaz białkowych
EP3353210B8 (en) 2015-09-25 2024-12-18 F. Hoffmann-La Roche AG Anti-tigit antibodies and methods of use
WO2017106647A1 (en) 2015-12-16 2017-06-22 Genentech, Inc. Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer
AU2017205089B2 (en) 2016-01-08 2023-10-05 F. Hoffmann-La Roche Ag Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
KR102500659B1 (ko) 2016-02-29 2023-02-16 제넨테크, 인크. 암에 대한 치료 및 진단 방법
WO2017180864A1 (en) 2016-04-14 2017-10-19 Genentech, Inc. Anti-rspo3 antibodies and methods of use
CA3019921A1 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
KR20190003957A (ko) 2016-04-15 2019-01-10 제넨테크, 인크. 암 모니터링 및 치료 방법
WO2017180581A1 (en) 2016-04-15 2017-10-19 Genentech, Inc. Diagnostic and therapeutic methods for cancer
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
WO2017205538A1 (en) 2016-05-24 2017-11-30 Genentech, Inc. Pyrazolopyridine derivatives for the treatment of cancer
MA45122A (fr) 2016-05-24 2019-04-10 Constellation Pharmaceuticals Inc Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer
JP2019527037A (ja) 2016-06-08 2019-09-26 ジェネンテック, インコーポレイテッド がんのための診断及び治療方法
CN109963871A (zh) 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 具有激动活性的多价及多表位抗体以及使用方法
JP7250674B2 (ja) 2016-08-08 2023-04-03 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト がんの治療及び診断方法
MX2019003934A (es) 2016-10-06 2019-07-10 Genentech Inc Métodos terapéuticos y de diagnóstico para el cáncer.
US11555076B2 (en) 2016-10-29 2023-01-17 Genentech, Inc. Anti-MIC antibodies and methods of use
CA3052670A1 (en) 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CN110582293B (zh) * 2017-03-31 2025-04-04 小利兰·斯坦福大学托管委员会 合成因子组合物及使用方法
JP2020516638A (ja) 2017-04-13 2020-06-11 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを処置する方法における使用のための、インターロイキン2イムノコンジュゲート、cd40アゴニスト、および任意選択のpd−1軸結合アンタゴニスト
MX2020000604A (es) 2017-07-21 2020-09-10 Genentech Inc Métodos terapéuticos y de diagnóstico para el cáncer.
WO2019033043A2 (en) 2017-08-11 2019-02-14 Genentech, Inc. ANTI-CD8 ANTIBODIES AND USES THEREOF
TWI827550B (zh) 2017-09-08 2024-01-01 美商建南德克公司 癌症之診斷及治療方法
EP3710001A4 (en) 2017-10-27 2021-07-14 University Of Virginia Patent Foundation COMPOUNDS AND PROCESSES FOR REGULATING, LIMITING OR INHIBITING THE EXPRESSION OF AVIL
CA3077664A1 (en) 2017-11-06 2019-05-09 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CA3087779A1 (en) 2018-01-15 2019-07-18 Epiaxis Therapeutics Pty Ltd Agents and methods for predicting response to therapy
AU2019225249A1 (en) 2018-02-26 2020-09-17 Genentech, Inc. Dosing for treatment with anti-tigit and anti-PD-L1 antagonist antibodies
AU2019275404A1 (en) 2018-05-21 2020-12-03 Bruker Spatial Biology, Inc. Molecular gene signatures and methods of using same
JP7399895B2 (ja) 2018-06-23 2023-12-18 ジェネンテック, インコーポレイテッド Pd-1軸結合拮抗薬、白金剤、およびトポイソメラーゼii阻害剤で肺癌を治療する方法
US20200171146A1 (en) 2018-07-18 2020-06-04 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
WO2020051099A1 (en) 2018-09-03 2020-03-12 Genentech, Inc. Carboxamide and sulfonamide derivatives useful as tead modulators
CA3111401A1 (en) 2018-09-19 2020-03-26 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
EP3857230B1 (en) 2018-09-21 2023-06-07 F. Hoffmann-La Roche AG Diagnostic methods for triple-negative breast cancer
AU2019361983A1 (en) 2018-10-18 2021-05-20 Genentech, Inc. Diagnostic and therapeutic methods for sarcomatoid kidney cancer
US20220098262A1 (en) * 2018-12-13 2022-03-31 Bang DING ANTIBODY-TUMOR NECROSIS FACTOR alpha FUSION PROTEIN AND ITS PREPARATION AND APPLICATIONS
CN113396230A (zh) 2019-02-08 2021-09-14 豪夫迈·罗氏有限公司 癌症的诊断和治疗方法
EP3931565A4 (en) 2019-02-27 2023-04-12 Epiaxis Therapeutics Pty Ltd METHODS AND AGENTS FOR ASSESSING T LYMPHOCYTE FUNCTION AND PREDICTING RESPONSE TO THERAPY
JP2022521773A (ja) 2019-02-27 2022-04-12 ジェネンテック, インコーポレイテッド 抗tigit抗体と抗cd20抗体又は抗cd38抗体とによる処置のための投薬
WO2020223233A1 (en) 2019-04-30 2020-11-05 Genentech, Inc. Prognostic and therapeutic methods for colorectal cancer
KR20220004744A (ko) 2019-05-03 2022-01-11 제넨테크, 인크. 항-pd-l1 항체를 이용하여 암을 치료하는 방법
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
PE20221449A1 (es) 2019-09-04 2022-09-21 Genentech Inc Agentes de union a cd8 y usos de los mismos
AU2020351734A1 (en) 2019-09-27 2022-04-14 Genentech, Inc. Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
CN114728936A (zh) 2019-10-29 2022-07-08 豪夫迈·罗氏有限公司 用于治疗癌症的双功能化合物
EP4055388A1 (en) 2019-11-06 2022-09-14 Genentech, Inc. Diagnostic and therapeutic methods for treatment of hematologic cancers
CA3155989A1 (en) 2019-11-13 2021-05-20 Jason Robert ZBIEG Therapeutic compounds and methods of use
CA3163950A1 (en) 2019-12-13 2021-06-17 Genentech, Inc. Anti-ly6g6d antibodies and methods of use
AU2020408562A1 (en) 2019-12-20 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021177980A1 (en) 2020-03-06 2021-09-10 Genentech, Inc. Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
EP4127724A1 (en) 2020-04-03 2023-02-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
JP2023523450A (ja) 2020-04-28 2023-06-05 ジェネンテック, インコーポレイテッド 非小細胞肺がん免疫療法のための方法及び組成物
EP3915576A1 (en) 2020-05-28 2021-12-01 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Chimeric antigen receptors specific for p95her2 and uses thereof
CN115916182A (zh) 2020-06-16 2023-04-04 基因泰克公司 用于治疗三阴性乳腺癌的方法和组合物
IL298946A (en) 2020-06-18 2023-02-01 Genentech Inc Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
WO2022002874A1 (en) 2020-06-30 2022-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
JP2023531305A (ja) 2020-06-30 2023-07-21 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 術前補助療法後の固形癌患者の再発及び/又は死亡のリスクを予測するための方法。
EP3939999A1 (en) 2020-07-14 2022-01-19 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
CN116568824A (zh) 2020-08-03 2023-08-08 基因泰克公司 淋巴瘤的诊断和治疗方法
EP4196612A1 (en) 2020-08-12 2023-06-21 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CA3193952A1 (en) 2020-10-05 2022-04-14 Bernard Martin Fine Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
JP2024506339A (ja) 2021-02-12 2024-02-13 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための二環式テトラヒドロアゼピン誘導体
EP4347603A1 (en) 2021-05-25 2024-04-10 Erasca, Inc. Sulfur-containing heteroaromatic tricyclic kras inhibitors
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
WO2023018699A1 (en) 2021-08-10 2023-02-16 Erasca, Inc. Selective kras inhibitors
JP2024541508A (ja) 2021-11-24 2024-11-08 ジェネンテック, インコーポレイテッド 治療用インダゾール化合物およびがんの治療における使用方法
WO2023097194A2 (en) 2021-11-24 2023-06-01 Genentech, Inc. Therapeutic compounds and methods of use
EP4253418A1 (en) 2022-03-29 2023-10-04 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof
CN119487067A (zh) 2022-04-01 2025-02-18 基因泰克公司 用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
AU2022458320A1 (en) 2022-05-11 2024-11-28 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
CN119856056A (zh) 2022-06-07 2025-04-18 基因泰克公司 用于确定包括抗pd-l1拮抗剂和抗tight拮抗剂抗体的肺癌治疗的疗效的方法
AU2023305619A1 (en) 2022-07-13 2025-01-23 F. Hoffmann-La Roche Ag Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AU2023309556A1 (en) 2022-07-19 2025-01-23 F. Hoffmann-La Roche Ag Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
CN119768401A (zh) 2022-08-11 2025-04-04 豪夫迈·罗氏有限公司 双环四氢硫氮杂䓬衍生物
CN119698413A (zh) 2022-08-11 2025-03-25 豪夫迈·罗氏有限公司 双环四氢硫氮杂䓬衍生物
IL316935A (en) 2022-08-11 2025-01-01 Hoffmann La Roche TETRAHYDROTHIAZEPINE DERIVATIVES CYCLES
AR130167A1 (es) 2022-08-11 2024-11-13 Hoffmann La Roche Derivados bicíclicos de tetrahidroazepina
WO2024085242A2 (en) 2022-10-21 2024-04-25 Kawasaki Institute Of Industrial Promotion Non-fouling or super stealth vesicle
AU2023367741A1 (en) 2022-10-25 2025-05-01 Genentech, Inc. Therapeutic and diagnostic methods for multiple myeloma
EP4406973A1 (en) 2023-01-27 2024-07-31 Fundació Privada Institut de Recerca de la SIDA-Caixa Antibodies and uses thereof for the treatment of infections caused by enveloped viruses
WO2024173842A1 (en) 2023-02-17 2024-08-22 Erasca, Inc. Kras inhibitors
WO2024233341A1 (en) 2023-05-05 2024-11-14 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024254455A1 (en) 2023-06-08 2024-12-12 Genentech, Inc. Macrophage signatures for diagnostic and therapeutic methods for lymphoma
WO2025024257A1 (en) 2023-07-21 2025-01-30 Genentech, Inc. Diagnostic and therapeutic methods for cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
US5470571A (en) * 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
ZA902949B (en) * 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
EP0491007B1 (en) * 1989-09-08 1996-03-13 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
ES2178635T3 (es) * 1990-11-09 2003-01-01 Stephen D Gillies Inmunoconjugados de citoquinas.
EP1362868A3 (en) * 1991-03-06 2004-02-11 MERCK PATENT GmbH Humanized and chimeric monoclonal antibodies that bind epidermal growth factor receptor (EGF-R)
JPH06509563A (ja) * 1991-07-05 1994-10-27 セラゲン・インコーポレイテッド 炎症性関節炎の治療用の表皮細胞成長因子受容体を標的とする分子
DE69327620T2 (de) * 1992-08-18 2000-08-03 Centro De Immunologia Molecular, Ciudad De La Habana Monoklonale Antikörper gegen den epidermalen Wachstumsfaktorrezeptor, Zellen und Verfahren zur ihrer Herstellung und sie erhaltende Zusammensetzungen
DK139193D0 (da) 1993-09-24 1993-12-13 Hartmann As Brdr Rektangulaer aegbakke
US5844093A (en) * 1994-03-17 1998-12-01 Merck Patent Gesellschaft Mit Beschrankter Haftung Anti-EGFR single-chain Fvs and anti-EGFR antibodies

Also Published As

Publication number Publication date
JPH07223968A (ja) 1995-08-22
KR950016781A (ko) 1995-07-20
HUT70471A (en) 1995-10-30
RU94045281A (ru) 1996-11-10
RU2129018C1 (ru) 1999-04-20
SK156294A3 (en) 1995-07-11
HU219680B (hu) 2001-06-28
NO944980D0 (no) 1994-12-22
AU688817B2 (en) 1998-03-19
DE69428764T2 (de) 2002-06-20
EP0659439A3 (en) 1996-12-04
HU9403784D0 (en) 1995-02-28
EP0659439B1 (en) 2001-10-24
EP0659439A2 (en) 1995-06-28
PL178793B1 (pl) 2000-06-30
DK0659439T3 (da) 2002-01-14
PT659439E (pt) 2002-04-29
UA41888C2 (uk) 2001-10-15
PL306474A1 (en) 1995-06-26
CZ330694A3 (en) 1995-10-18
SK283494B6 (sk) 2003-08-05
CA2138928A1 (en) 1995-06-25
US6979726B1 (en) 2005-12-27
CZ289099B6 (cs) 2001-11-14
NO944980L (no) 1995-06-26
NO315903B1 (no) 2003-11-10
AU8159394A (en) 1995-06-29
DE69428764D1 (de) 2001-11-29
JP2006298936A (ja) 2006-11-02
CA2138928C (en) 2009-02-17
ZA9410282B (en) 1995-08-29
ATE207366T1 (de) 2001-11-15

Similar Documents

Publication Publication Date Title
ES2166368T3 (es) Inmunoconjugados.
BRPI0507169A (pt) polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
ATE173766T1 (de) Monoklonale antikörper, die mit cachectin reagieren
BRPI0514115A (pt) terapia de combinação empregando-se proteìnas de fusão de transferrina compreendendo glp-1
EA199800946A1 (ru) Концентрированный препарат антител
DK25084A (da) Human-human hybridoma mod neoplasmer
CR7875A (es) Variantes de inmunoglobina y usos de esto
DE3382474D1 (de) Menschliche monoklonale antikoerper gegen bakterielle toxine.
DE69333574D1 (de) Gegen c-erb b-2 (her-2/neu) vewandte oberflächenantigene gerichtete immuntoxine
AR005941A1 (es) Composicion cosmetica, su uso, y procedimiento de tratamiento cosmetico de substancias queratinicas tales como el cabello empleando dicha composicion
ES2136673T3 (es) Utilizacion del factor de crecimiento de los queratinocitos para la obtencion de medicamentos.
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
BR0206905A (pt) Métodos para tratar ou prevenir distúrbios da pele empregando-se agentes de ligação de cd2
ATE402995T1 (de) Akt-3 nukleinsäure, polypeptide und deren verwendung
DE58906338D1 (de) Kombination von Angiotensin-Converting-Enzyme-Hemmern mit Kaliumkanal-Modulatoren sowie deren Verwendung in Arzneimitteln.
ES2061566T3 (es) Anticuerpos monoclonales contra la proteina e7 del papilomavirus humano tipo 16, procedimiento para su preparacion, asi como su empleo.
CA2121358A1 (en) Thymidine phosphorylase for use in the modulation of cellular proliferation or chemotaxis
ES2075179T3 (es) Procedimiento de triturado en humedo para el maiz ensilado.
ES2136199T3 (es) Expresion multicistronica de genes recombinantes en celulas bacterianas.
ATE299934T1 (de) Menschliche scf, eine spleissvariante davon,ihre pharmazeutische verwendung
DE60141169D1 (de) Verwendung einer zusammensetzung mit n-acetylcystein zur konditionierung von stammzellen
ES2175550T3 (es) Procedimiento para inducir proteinas de accion terapeutica.
DOP2025000005A (es) SOLUCIONES FARMACÉUTICAS DE ANTICUERPOS ANTI-N3pGlu Aß Y USOS DE ESTAS.
ATE116962T1 (de) Mentholderivate mit spasmolytik aktivität.
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 659439

Country of ref document: ES

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载